Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP, Chief Commercial Officer

VP, Finance (Interim PAO)

SVP, Chief Financial Officer

EVP, CLO, Alkermes, Inc.

EVP, Chief Operating Officer

SVP, Corp Dev., Alkermes, Inc.

EVP R&D, Chief Medical Officer

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-18	Premium	sold	Premium	Premium	Premium	SVP, Chief Commercial Officer
2024-02-27	Premium	sold	Premium	Premium	Premium	VP, Finance (Interim PAO)
2024-02-23	Premium	acquired	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-02-23	Premium	acquired	Premium	Premium	Premium	VP, Finance (Interim PAO)
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP, CLO, Alkermes, Inc.
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Operating Officer
2024-02-23	Premium	acquired	Premium	Premium	Premium	SVP, Corp Dev., Alkermes, Inc.
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Commercial Officer
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP, Chief Operating Officer
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-02-23	Premium	acquired	Premium	Premium	Premium	SVP, Chief Commercial Officer
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP R&D, Chief Medical Officer
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	EVP R&D, Chief Medical Officer
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	VP, Finance (Interim PAO)
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	EVP, CLO, Alkermes, Inc.
2024-02-23	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Corp Dev., Alkermes, Inc.
2024-02-22	Premium	sold (taxes)	Premium	Premium	Premium	EVP R&D, Chief Medical Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	EVP, Chief Operating Officer
2024-02-22	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Commercial Officer
2024-02-22	Premium	sold (taxes)	Premium	Premium	Premium	VP, Finance (Interim PAO)
2024-02-22	Premium	acquired	Premium	Premium	Premium	SVP, Corp Dev., Alkermes, Inc.
2024-02-22	Premium	acquired	Premium	Premium	Premium	VP, Finance (Interim PAO)
2024-02-22	Premium	acquired	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-02-22	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Operating Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	EVP, CLO, Alkermes, Inc.

ALKS - Alkermes PLC Stock Price, Fair Value and News

Latest Insider Trading transactions for ALKS